Aclaris stock soars for second day on licensing deal, analyst upgrades
Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...
RealReal price target raised to $5.50 from $4 at BTIG
BTIG analyst Marvin Fong raised the firm’s price target on RealReal (REAL) to $5.50 from $4 and keeps a Buy rating on the shares. The firm ...
Le Lézard9h
Simulations Plus to Participate in the BTIG Digital Health Forum
Simulations Plus, Inc. ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, ...
Fintel on MSN10h
BTIG Upgrades Aclaris Therapeutics (ACRS)
Fintel reports that on November 19, 2024, BTIG upgraded their outlook for Aclaris Therapeutics (NasdaqGS:ACRS) from Neutral ...
Aclaris Therapeutics upgraded to Buy from Neutral at BTIG
BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired ...